Annual Report 2003 Aventis - Sanofi

More documents

Recommendations

Info

3
Meeting Future Challenges >> 4
Page 1 and 2: Life can’t wait. Aventis 2003 Ann
Page 3 and 4: Financial Highlights Net Sales (in
Page 5 and 6: Therapeutic Area Key Developments R
Page 7: Letter to Shareholders Dear Shareho
Page 11 and 12: Report of the Supervisory Board Dea
Page 13 and 14: 8
Page 16 and 17: 11
Page 18 and 19: Aventis Strategic Brands Taxotere (
Page 20: Expert Opinion on Oncology >> 15
Page 23 and 24: Medical Background Diabetes mellitu
Page 25 and 26: Production and Manufacturing Meetin
Page 28 and 29: 23
Page 30 and 31: Aventis Human Vaccines Pediatric co
Page 32: Expert Opinion on Immunization >> 2
Page 35 and 36: Medical Background Deep vein thromb
Page 37 and 38: Sales and Marketing The Power of Ev
Page 40 and 41: 35
Page 42 and 43: Aventis Strategic Brands Allegra /
Page 44 and 45: Expert Opinion on Infectious Diseas
Page 46 and 47: Targocid (teicoplanin) is a consist
Page 48 and 49: Key Regulatory Achievements in 2003
Page 50 and 51: program is designed to enable Avent
Page 52 and 53: Africa, we supplied 60 000 vials of
Page 54 and 55: Nutrition and Aventis CropScience i
Page 56 and 57: 51
Page 58 and 59:
still constitute a signifi cant par
Page 60 and 61:
Your Contacts Your Contacts at Aven
Page 62 and 63:
Brand names appearing in italics th
show all

Annual Report 2003 Aventis - Sanofi

Create successful ePaper yourself

Delete template?

Save as template?